Femasys Inc. (FEMY)
$1.22
Rating:
Recommendation:
-
| Symbol | FEMY |
|---|---|
| Price | $1.22 |
| Beta | 0.000 |
| Volume Avg. | 0.02M |
| Market Cap | 14.413M |
| Shares () | - |
| 52 Week Range | 0.57-3.71 |
| 1y Target Est | - |
| DCF Unlevered | FEMY DCF -> | |
|---|---|---|
| DCF Levered | FEMY LDCF -> | |
| ROE | -52.45% | Strong Sell |
| ROA | -58.10% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 11.25% | Neutral |
| P/E | 4.07 | Buy |
| P/B | 0.80 | Buy |
Latest FEMY news
About
Download (Excel)Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.